Roche Holding PT receives Investment Bank Analyst Rating Update
Biogen stock is getting favorable ratings after successful trial results for its latest Alzheimer's treatment Lecanemab is Biogen's latest attempt to cure the disease after its...
Inflation worries continue to weigh on equity markets Earnings season will likely increase volatility ETFs offer investors ability to diversify Earnings season has started with...
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
|Average||47.80 (+24.64% Upside)|
|No. of Analysts||2|